FDA approves Takeda’s first proton-pump inhibitor with trademarked Dual Delayed Release technology
OSAKA, Japan The Food and Drug Administration has approved the first proton-pump inhibitor with the trademarked Dual Delayed Release technology for treating gastro-esophageal reflux disease, the drug’s manufacturer announced.
Takeda Pharmaceutical Co. made the announcement Friday with its North American subsidiary that the FDA had approved Kapidex (dexlansoprazole). The drug, a once-daily, delayed-release capsule, is used to treat heartburn associated with symptomatic, non-erosive GERD, healing erosive esophagitis and maintaining healed EE. The capsules will be available in 30 mg and 60 mg strengths.
“Through the discovery, development and commercialization of new medicines, Takeda has been a leader in acid-related therapy for more than 15 years and is committed to bringing new therapies to market,” Takeda Pharmaceuticals North America CEO Alan MacKenzie stated.
Proton-pump inhibitors work by turning off acid pumps in the stomach, thus reducing production of the acid that causes GERD.
AstraZeneca announces plans to lay off 6,000 employees by 2013
NEW YORK Drug maker AstraZeneca plans to lay off 6,000 employees by 2013, the Anglo-Swedish company announced Thursday.
The layoffs add to the 9,000 jobs AstraZeneca said it would cut in 2007. The company has 65,000 employees.
Amid the worldwide economic downturn, several drug makers have announced layoffs. Pfizer announced this week that it would lay off more than 8,000 workers as part of its acquisition of Wyeth.
Bartell Drugs to offer free health screenings at 11 of its stores in Feb.
SEATTLE Bartell Drugs, which operates stores in the Seattle area, said it would offer free health screenings at 11 of its stores next month. The stores will offer tests for blood glucose, cholesterol and blood pressure in partnership with One Touch, Nature Made and CIA Health Screenings. Customers will receive results immediately.
“We are extremely pleased to offer these screenings, because the results can provide our customers with important front-line indicators in the fight against diabetes, heart disease and stroke,” chairman and CEO George Bartell said in a statement.
The screenings will take place from 10 a.m. to 4 p.m. every day of the month starting Feb. 16.